Patents Assigned to Merck
  • Patent number: 6403612
    Abstract: A thrombin receptor antagonist having the formula or a pharmaceutically acceptable salt thereof, useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Philippe G. Nantermet, James C. Barrow, Harold G. Selnick
  • Patent number: 6403596
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, David A. Claremon, John W. Butcher, Cory R. Theberge
  • Patent number: 6403347
    Abstract: Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Gerald F. Bills, Russell B. Lingham, Ali Shafiee, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink, Fernando Pelaez, Ana M. Teran
  • Patent number: 6403584
    Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Clare E. Gutteridge, William K. Hagmann, Theodore M. Kamenecka
  • Patent number: 6403171
    Abstract: TN and HTN liquid-crystal displays having very short response times and good steepness values and angle dependencies, are obtained using nematic liquid-crystal mixtures which comprise compounds of formula IA in combination with compounds of the formula IC: in which R1 to R3, L1, Z, and C are defined herein.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: June 11, 2002
    Assignee: Merck GmbH
    Inventors: Harald Hirschmann, Marcus Reuter
  • Publication number: 20020068739
    Abstract: The present invention relates to the compounds of formula (I) in which X, R1, R2 and R3 are as defined in claim 1. These compounds are cholesteryl acyl transferase (ACAT) inhibitors.
    Type: Application
    Filed: November 1, 2001
    Publication date: June 6, 2002
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Diedier Festal, Jean Yves Nioche, Guy Augert, Jacques Deserprit
  • Patent number: 6399611
    Abstract: Aralkylpyridazinone derivatives of the formula I and their physiologically acceptable salts in which R1, R2, R3, R4, R5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflammatory processes and of allergies, asthma and autoimmune disorders.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: June 4, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Michael Wolf, Norbert Beier
  • Patent number: 6399640
    Abstract: Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr;, &dgr; and/or &ggr; mediated diseases, disorders and conditions.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Soumya P. Sahoo, Conrad Santini, Julia K. Boueres, James V. Heck, Edward Metzger, Victoria K. Lombardo
  • Patent number: 6399597
    Abstract: Compounds of formula I are disclosed. as well as pharmaceutically acceptable salts thereof. The naphthosultam is substituted with various substituent groups including at least one cationic group —A—Q—L—B. The carbapenems of the invention are effective against susceptible bacterial organisms, including methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger, Wanying Sun
  • Patent number: 6399044
    Abstract: The invention related to powder mixtures containing formaldehyde- and/or formic acid-releasing compounds which have skin-tanning properties, which powder mixtures contain an agent which forms sulphite ions and, if appropriate, a stabilizer, and to the preparation and use of these powder mixtures for manufacturing cosmetic or pharmaceutical preparations.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: June 4, 2002
    Assignee: Merck Patent Gesellschaft Mit
    Inventors: Thekla Kurz, Sabine Hitzel, Roland Martin, Ralf Emmert
  • Patent number: 6399162
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, comprising one or more compounds of the general formula I and simultaneously one or more compounds of the general formula II in which R is H or an alkyl or alkoxy radical having 1 to 15 carbon atoms, Y is F, OCF3 or OCHF2, and R′, independent of the radical selected in the formula I, is as defined for R.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Volker Reiffenrath, Brigitte Schuler, Kazuaki Tarumi
  • Patent number: 6399786
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Matthew J. Wyvratt
  • Patent number: 6399592
    Abstract: Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM 210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Donna T. Whiteford
  • Patent number: 6399608
    Abstract: A pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound, which is a modulator of the benzodiazepine binding site of the human GABAA receptor, having a binding affinity for the &agr;3 subunit of the human GABAA receptor of 10 nM or less, which elicits at least a 40% potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the &agr;3 subunit of &agr;3 and which elicits at most a 30% potentiation of the GABA EC20 response in stably transfected cell lines expressing the &agr;1 subunit of the human GABAA receptor is disclosed for simultaneous, separate or sequential administration.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Gerard Raphael Dawson
  • Patent number: 6399636
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Patent number: 6398962
    Abstract: The invention relates to use of monolithic sorbents for preparative separation processes, specially for processes according to the simulated moving bed (SMB) principle.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck KGaA
    Inventors: Karin Cabrera, Dieter Lubda, Michael Schulte, Andreas Meudt, Olivier Ludemann-Hombourger, Gerhard Wieland, Kristina Czerny, Axel Delp, Edith Dicks, Alexander Kraus
  • Patent number: 6398862
    Abstract: The invention relates to a non-dusting homogeneous pigment preparation notable in that it comprises at least 40% by weight of one or more pearl lustre pigments.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: June 4, 2002
    Assignee: Merck Patent Gesellschaft mit Beschraenkter Haftung
    Inventors: Wolfgang Hechler, Gerhard Herget, Brigitte Husseini
  • Patent number: 6399619
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    Type: Grant
    Filed: April 4, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Scott Berk, Charles G. Caldwell, Kevin T. Chapman, Jeffrey Hale, Christopher Lynch, Malcolm MacCoss, Sander G. Mills, Christopher Willoughby
  • Publication number: 20020064607
    Abstract: The invention relates to TN and STN liquid-crystal displays and to the novel nematic liquid-crystal mixtures used therein, characterized in that they comprise one or more compounds of the formula I 1
    Type: Application
    Filed: June 19, 2001
    Publication date: May 30, 2002
    Applicant: Merck Patent GmbH
    Inventors: Harald Hirschmann, Martina Weidner, Sven Schupfer, Peer Kirsch
  • Publication number: 20020065240
    Abstract: The present invention relates to methods of gene therapy to promote angiogenesis in the treatment of peripheral, cardiac and other pathological tissue ischemias utilizing a DNA molecule (SEQ ID NO:1) which encodes human VEGF145, set forth in SEQ ID NO:2.
    Type: Application
    Filed: March 19, 2001
    Publication date: May 30, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Kenneth A. Thomas, Richard L. Kendall, Andrew J. Bett, William R. Huckle